Q1 2025. Management View. CEO Robert Mauch highlighted strong Q1 performance with 13% revenue growth and a 14% increase in adjusted EPS.

The PBM system intentionally blocks lower-cost, FDA-approved biosimilars from being available to patients. Biosimilars are the commonsense, bipartisan solution to out-of-control prescription drug ...

Surveying the next 12 months, J&J expects to chart roughly 3% sales growth to $91.3 billion in 2025 by “overcoming headwinds associated with U.S. biosimilar entries for Stelara,” as well as ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, one of its top-sellers.

Tocilizumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Rheumatoid Arthritis. According to GlobalData, Pre-Registration drugs for Rheumatoid Arthritis ...

Subscribe to our FREE Newsletter, or Telegram and WhatsApp channels for the latest stories and updates. Malaysia’s first glass water slide is ready to welcome visitors at i-City Shah Alam as part of ...

We list the best free presentation software, to make it simple and easy to create professional presentations without a subscription to Microsoft PowerPoint. While PowerPoint is the market leader ...

Additionally, HSP60 expression was evaluated using immunohistochemistry staining on full tumor slides; two independent pathologists randomly reviewed them on 2 separate occasions. Staining ...

Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing ...

INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released its First Quarter 2025 Biosimilar Market Report, marking the eighth edition of the Quarterly Biosimilar ...

To pave a pathway to producing a biosimilar version of atezolizumab, Mehmet Inan, PhD, director of the Izmir Biomedicine and Genome Center in Turkey, and his colleagues developed a bioprocess for ...

The brokerage's optimism stems from an expected operational turnaround for Biocon, driven by key biosimilar launches and a recovery in generics sales. HSBC highlighted several factors that could ...